Some possibilities of the use of atypical neuroleptics in paedopsychiatry;Nektere moznosti uziti atypickych neuroleptik v pedopsychiatrii

Cesko-Slovenska Pediatrie

Volumn 55, Issue 9, 2000, Pages 578-584

  Hrdlička, Michal ^a   Propper, L ^b   Bares M ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE

Author keywords

Atypical neuroleptics; Bipolar affective disorder; Clozapine; Early onset schizophrenia; Olanzapine; Pervasive developmental disorders; Risperidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; AUTISM; BONE MARROW TOXICITY; CHILD; DRUG EFFICACY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NEUROTOXICITY; ONSET AGE; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0343714592     PISSN: 00692328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Armenteros, J. L., Whitaker, A. H., Welikson, M. et al.: Risperidone in adolescents with schizophrenia. J. Amer. Acad. Child Adolesc. Psychiat., 36, 1997, č. 5, s. 694-700.
2. Beasley, C. M., Tollefson, G. D., Tran, P. V.: Efficacy of olanzapine: an overview of pivotal clinical trials. J. clin. Psychiat., 58, 1997, Suppl. 10, s. 7-12.
3. Bleuler, M.: The Schizophrenic Disorders: Long Term Patient and Family Studies. New Haven, Yale University Press 1978.
4. Carpenter, W. T., Strauss, J.: The prediction of outcome in schizophrenia. V: Eleven year follow-up of the IPSS cohort. J. Nerv. Ment. Dis., 179, 1991, s. 517-525.
5. Conley, R. R., Tamminga, C. A., Bartko, J. J. et al.: Olanzapine compared with chlorpromazine in treatment - resistant schizophrenia. Amer. J. Psychiat., 155, 1998, s. 914-920.
6. Češková, E.: Časná detekce a prevence schizofrenie. Čs. Psychiat., 93, 1997, č. 4, s. 202-210.
7. Drtílková, I.: Risperidon u dětí a adolescentů se schizofrenními poruchami. Čs. Psychiat., 95, 1999, Suppl. 2, s. 22-29.
8. Drtílková, I.: Předběžné zkušenosti s risperidonem u dětí s pervazivními vývojovými poruchami. Čs. Psychiat., 95, 1999, Suppl. 2, s. 18-21.
9. The Expert Consensus Panel for Bipolar Disorder: Treatment of bipolar disorder. J. clin. Psychiat., 57, 1996, Suppl. 12A, s. 11-88.
10. Findling, R. L., Maxwell, K., Wiznitzer, M.: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull., 33, 1997, č. 1, s. 155-159.
11. Fisman, S., Steele, M.: Use of risperidone in pervasive developmental disorders: a case series. J. Child Adolesc. Psychopharmacol., 6, 1996, č. 3, s. 177-190.
12. Frazier, J. A., Gordon, C. T., McKenna, K. et al.: An open trial of clozapine in 11 adolescents with childhood - onset schizophrenia. J. Amer. Child Adolesc. Psychiat., 33, 1994, č. 5, s. 658-663.
13. Garaj, V., Garajová, E.: Clozapin v liečbe u adolescentov. Čs. Psychiat., 94, 1998, č. 6, s. 341-345.
14. Gerlach, J., Peacock,. L.: New antipsychotics: the present status. Int. clin. Psychopharmacol., 10, 1995, Suppl. 3, s. 39-48.
15. Grcevich, S. J., Findling, R. L., Schulz, S. C. et al.: Risperidone in the treatment of children and adolescents with psychotic illness: a retrospective review. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association. Miami, May 25, 1995.
16. Gross, G., Huber, G., Schüttler, R.: Die Beeinflussung des Langzeitverlaufs schizophrener Krankheiten durch somatotherapeutische Maßnahmen. Psychiat. Clin., 13, 1980, s. 179-192.
17. Hardan, A., Johnson, K., Johnson, C., Hrecznyj, B.: Case study: risperidone treatment of children and adolescents with developmental disorders. J. Amer. Acad. Child Adolesc. Psychiat., 35, 1996. č. 11, s. 1551-1556.
18. Harteveld, E. M., Buitelaar, J. K.: Autism: role of drug treatment and a guide to its use. CNS Drugs, 8, 1997, č. 3, s. 227-236.
19. Horrigan, J. P., Barnhill, L. J.: Risperidone and explosive aggresive autism. J. Autism Develop. Disord., 27, 1997, č. 3, s. 313-323.
20. Hrdlička, M.: Současné názory na indikační spektrum clozapinu. In: Sikora, J., Fišar, Z., Petrovický, P., Jirák, R. (editoři): Biologické podklady psychických poruch. Sborník 8. celostátní konference biologické psychiatrie. Praha, Galén 1997, s. 91-93.
21. Hrdlička, M., Propper, L., Vinař, O. et al.: Risperidon v akutní léčbě schizofrenie v adolescenci. Čs. Psychiat., 94, 1998, č. 3, s. 131-136.
22. Hrdlička, M., Propper, L., Bareš, M.: Atypická neuroleptika v léčbě schizofrenie s časným začátkem. Čs. Psychiat., 95, 1999, č. 3, s. 157-164.
23. Hrdlička, M., Bareš, M., Propper, L.: Postavení neuroleptik v léčbě bipolární poruchy. Čs. Psychiat., 95, 1999, č. 7, s. 453-461.
24. Junghans, J., Dittmann, R. W.: Olanzapine in the treatment of adolescents with schizophrenia and other psychotic disorders. Schizophr. Res., 36, 1999, Suppl., s. 283.
25. Kapur, S.: Co nám říkají zobrazovací receptorové studie o léčbě schizofrenie? Psychiatrie, 2, 1998, č. 4, s. 213-215.
26. Kerwin, R. W.: The new atypical antipsychotics. Brit. J. Psychiat., 164, 1994, s. 141-148.
27. Kowatch, R. A., Suppes, T., Gilfillan, S. K., Fuentes, R. M.: Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J. Child Adolesc. Psychopharmacol., 5, 1995, č. 4, s. 241-253.
28. Krishnamoorthy, J., King, B. H.: Open - label olanzapine treatment in five preadolescent children. J. Child Adolesc. Psychopharmacol., 8, 1998, č. 2, s. 107-113.
29. Kumra, S., Frazier, J. A., Jacobsen, L. K. et al.: Childhood - onset schizophrenia: a double-blind clozapine - haloperidol comparison. Arch. Gen. Psychiat., 53, 1996, č. 12, s. 1090-1097.
30. Kumra, S., Jacobsen, J. K., Lenane, M. et al.: Childhood - onset schizophrenia: an open - label study of olanzapine in adolescents. J. Amer. Acad. Child Adolesc. Psychiat., 37, 1998, č. 4, s. 377-385.
31. Levkowitz, Y., Kronnenberg, Y., Kaysar, N. et al.: Clozapine in adolescence onset schizophrenia. Harefuah, 127, 1994, č. 1 - 2, s. 16-18.
32. Liebermann, J. A.: Prediction of outcome in first-episode schizophrenia. J. clin. Psychiat., 54, 1993, Suppl. 3, s. 13-17.
33. Lieberman, J. A.: Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. clin. Psychiat., 57, 1996, Suppl. 11, s. 68-71.
34. Malá, E.: Risperidon, kognitivní funkce a pedopsychiatrické kazuistiky. Čs. Psychiat., 95, 1999, Suppl. 2, s. 42-64.
35. Mandoki, M. W.: Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J. Child Adolesc. Psychopharmacol., 5, 1995, č. 1, s. 49-67.
36. Mandoki, M.: Olanzapine in the treatment of early onset schizophrenia in children and adolescents. Biol. Psychiat., 41, 1997, Suppl. 7S, s. 22.
37. Marder, S. R.: Clinical experience with risperidone. J. clin. Psychiat., 57, 1996, Suppl. 9, s. 57-61.
38. McDougle, C. J., Holmes, J. P., Carlson, D. C. et al.: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiat., 55, 1998, č. 7, s. 633-641.
39. McKenna, P. J., Bailey, P. E.: The strange story of clozapine. Brit. J. Psychiat., 162, 1993, s. 32-37.
40. 2 pKi values. J. Pharmacol. Exp. Ther., 251, 1989, s. 238-246.
41. Meltzer, H. Y.: Leponex: review of current results. Basel, Sandoz Pharma 1996.
42. Nicholson, R., Award, G., Sloman, L.: An open trial of risperidone in young autistic children. J. Amer. Acad. Child Adolesc. Psychiat., 37, 1998, č. 4, s. 372-376.
43. Ondrejka, I., Frank, V., Baška, T. et al.: Risperidon v liečbe schizofrénie s včasným začiatkom. Psychiatria, 5, 1998, č. 1, s. 48-50.
44. Potenza, M. N., Holmes, J. P., Kanes, S. J. et al.: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J. clin. Psychopharmacol., 19, 1999, s. 37-44.
45. Rapin, I.: Autism. New Engl. J. Med., 337, 1997, č. 2, s. 97-104.
46. Remschmidt, H. E., Schulz, E., Martin, M. et al.: Childhood - onset schizophrenia: history of the concept and recent studies. Schizophr. Bull., 20, 1994, č. 4, s. 727-745.
47. Segal, J., Berk, M., Brook, S.: Risperidone compared with both lithium and haloperidol in mania: a double-blind randomised controlled trial. Clin. Neuropharmacol., 31, 1998, č. 3, s. 176-180.
48. Siefen, G., Remschmidt, H.: Behandlungsergebnisse mit clozapin bei schizophrenen Jugendlichen. Z. Kinder Jugendpsychiatr., 14, 1986, s. 245-257.
49. Švestka, J.: Clozapin. Praha, Maxdorf 1998.
50. Švestka, J.: Nová antipsychotika II. generace: olanzapin. Psychiatrie, 2, 1998, č. 2, s. 7-15.
51. Turetz, M., Mozes, T., Toren, P. et al.: An open trial of clozapine in neuroleptic - resistant childhood - onset schizophrenia. Brit. J. Psychiat., 170, 1997, s. 507-510.
52. Zarate, C. A., Tohen, M., Baldessarini, R. J.: Clozapine in severe mood disorders. J. clin. Psychiat., 56, 1995, č. 9, s. 411-417.
53. Zuddas, A., Ledda, M. G., Fratta, A. et al.: Clinical effects of clozapine on autistic disorder. Amer. J. Psychiat., 153, 1996, č. 5, s. 738.